abstract |
A saline or buffer-based formulation comprising 10 mg/mL or more of iduronate-2-sulfatase (I2S) for use in a method of treating Hunters syndrome in a subject wherein said method comprises directly administering said formulation into the cerebrospinal fluid of said subject by intraparenchymal, intracerebral, intracerebral intraventricular (ICV), or intrathecal (IT) administration. |